The historical rank and industry rank for Evogene's Days Payable or its related term are showing as below:
EVGN'
s Days Payable Range Over the Past 10 Years
Min: 48.28 Med: 306.28 Max: 1101.97
Current: 48.28
During the past 13 years, Evogene's highest Days Payable was 1101.97. The lowest was 48.28. And the median was 306.28.
EVGN's Days Payable is ranked worse than 68.61% of 704
companies
in the Biotechnology industry
Industry Median: 113.56
vs EVGN: 48.28
Evogene's Days Payable
declined
from Mar. 2025 (51.45) to Mar. 2026 (0.00).
It may suggest that Evogeneaccelerated paying its suppliers.
Evogene Days Payable Related Terms
Evogene Days Payable Historical Data
* Premium members only.
The historical data trend for Evogene's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Evogene's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evogene Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evogene's Days Payable distribution charts can be found below:
* The bar in red indicates where Evogene's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Evogene's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evogene (EVGN) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Evogene and its competitors. Over the past decade, Evogene's Days Payable has ranged from 48.28 to 1,101.97. According to the industry distribution chart, Evogene ranks #483 out of 704 companies in the Biotechnology industry, placing it in the top 68.6%.
Is Evogene's Days Payable too high?
Evogene's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 48.28 to a high of 1,101.97. Based on the distribution chart, Evogene ranks #483 out of 704 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Evogene has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Evogene's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Evogene ranks #483 out of 704 companies for Days Payable. This places Evogene in the lower half of its industry. The industry median Days Payable is 113.56. Historically, Evogene's own Days Payable has ranged from 48.28 to 1,101.97 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Evogene and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evogene's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evogene stock overvalued right now?
Based on GuruFocus' analysis, Evogene (EVGN) is currently considered Fairly Valued. The stock's GF Value™ is $0.45, compared to a current price of $0.44 — trading 2% below its estimated fair value. The current Days Payable is 0.00. Evogene's overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Evogene (EVGN), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evogene (EVGN) Overvalued in 2026?
Based on GuruFocus' analysis, Evogene stock appears to be undervalued.
The current stock price of $0.44 is trading 2% below its estimated GF Value™ of $0.45.
GuruFocus considers Evogene to be Fairly Valued.
Key valuation signals for EVGN:
Days Payable: 0.00
GF Value™: $0.45 vs. price of $0.44 (2% below fair value)
No single metric tells the full story. See the EVGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
33GF Score
Get the complete analysis for EVGN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVGN has been successfully added to your 
